New drug shows promise in hitting Hard-to-Treat brain cancers
NCT ID NCT05076513
First seen Mar 15, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study tests a drug called niraparib in people with two types of brain tumors: newly diagnosed glioblastoma and recurrent IDH-mutant glioma with ATRX loss. The goal is to see if the drug reaches the tumor and slows its growth. Up to 42 participants will receive niraparib before and after surgery, with some also getting standard radiation. The trial is in an early phase, so it focuses on safety and how the drug works in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
Conditions
Explore the condition pages connected to this study.